Therapy of primary and metastatic liver cancer by human iPS cell‐derived myeloid cells producing interferon‐β
Background iPS‐ML are myeloid lineage cells with a proliferative capacity derived from induced pluripotent stem (iPS) cells. This study aimed to examine therapeutic effect of iPS‐ML producing interferon‐β (iPS‐ML/IFN‐β) towards primary and metastatic liver cancer and investigate the mechanism of tha...
Saved in:
Published in | Journal of hepato-biliary-pancreatic sciences Vol. 24; no. 2; pp. 109 - 119 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
01.02.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
iPS‐ML are myeloid lineage cells with a proliferative capacity derived from induced pluripotent stem (iPS) cells. This study aimed to examine therapeutic effect of iPS‐ML producing interferon‐β (iPS‐ML/IFN‐β) towards primary and metastatic liver cancer and investigate the mechanism of that effect.
Methods
We established a xenograft model of liver metastasis by injecting the spleen of SCID mice with MKN‐45 human gastric cancer cells and also a primary liver cancer model by injecting SK‐HEP‐1 human hepatocellular carcinoma cells into the liver. After cancer lesions were established, iPS‐ML/IFN‐β was administered by intraperitoneal injection, and therapeutic effect was evaluated.
Results
The i.p. injection of iPS‐ML/IFN‐β resulted in a significant retardation of cancer progression and prolonged mouse survival. The infiltration of i.p. administered iPS‐ML into tumor lesions located below the liver capsule was observed, suggesting tumor‐directed migration and penetration of the liver capsule by iPS‐ML. The IFN‐β concentration in the liver was maintained at levels sufficient to exert an anti‐cancer effect for at least 3 days post‐injection, accounting for the potent therapeutic effect obtained by injection two to three times per week.
Conclusions
This study demonstrates the therapeutic potential of the iPS‐ML/IFN‐β in patients with liver cancer.
HighlightSakisaka and colleagues demonstrated the therapeutic effect of intraperitoneal injection of induced pluripotent stem cell‐derived myeloid cells producing interferon‐β against metastatic and primary liver cancer in xenograft cancer models. The results suggest that this therapy is beneficial for cancer patients, even for those with simultaneous peritoneal dissemination and liver metastasis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1868-6974 1868-6982 |
DOI: | 10.1002/jhbp.422 |